The merger announced Thursday of a Lexington-based cancer biotech with a Pennsylvania-based firm specializing in liver disease may look like a long-distance relationship of, if not opposites, at least very different drug companies.
But love was in the air. Literally, as the marriage of the two companies, announced yesterday, was spurred in part by the actual nuptials of one company's CEO and the director at another.
Synta Pharmaceuticals (Nasdaq: SNTA) in Lexington is a 15-year old biotech that’s…
↧